The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).
 
Nizar J. Bahlis
Honoraria - Abbvie; Amgen; Celgene; Janssen; Karyopharm Therapeutics; Sanofi; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Pfizer; Sanofi; Takeda
Research Funding - Celgene (Inst); Janssen (Inst)
 
Jeffrey A. Zonder
Consulting or Advisory Role - Alnylam; Amgen; Bristol-Myers Squibb; Caelum Biosciences; Celgene; Intellia Therapeutics; Janssen; Oncotherapeutics; Prothena; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst)
 
Susan Wroblewski
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Ming Qi
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Thomas Renaud
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Carolyn Chang Jackson
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Thierry Facon
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi; Takeda
Speakers' Bureau - celgene; Janssen; Takeda